^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | BT8009 (Microtubule inhibitor, Nectin-4-targeted peptide-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Title:
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Published date:
01/04/2023
Excerpt:
Bicycle Therapeutics plc...announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle’s BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.
